Porownywarka

PNC27 vs KPV side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

PNC27KPV

Udostępnij porównanie peptydów

Wlasciwosc	PNC27	KPV
Kategoria	Odporność	Odporność
Znany tez jako	PNC-27, p53-HDM2 Disruptor Peptide, Anti-Cancer Peptide PNC-27	Lys-Pro-Val, Alpha-MSH fragment
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Preclinical; reported in-vitro, ex-vivo human cancer-tissue, and animal research, with no human clinical trials reported. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical research ongoing; no human clinical-trial benefit evidence was provided Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Cancer research; tumor targeting; oncology research.	Gut inflammation, IBD, skin conditions and anti-inflammatory activity
Jak dziala	The source describes a p53-derived binding segment engaging HDM-2/MDM2 reported at the surface of some cancer cells. It proposes that the peptide's amphipathic helix-loop-helix conformation can enter the membrane and form pores, leading to necrotic lysis rather than apoptosis. It also reports mitochondrial membrane disruption after entry. Reported selectivity is attributed to normal cells lacking membrane-associated HDM-2, but this remains preclinical evidence.	KPV is described as a short alpha-MSH-derived peptide with a proposed anti-inflammatory mechanism. In the supplied evidence, KPV uptake is linked to PepT1 transport, particularly in inflamed intestinal tissue. After cellular entry, laboratory findings associate KPV with dampened NF-kB activity and reduced production of inflammatory mediators such as TNF-alpha, IL-1beta and IL-6. The source also states that KPV does not appear to act through the classic melanocortin receptors used by alpha-MSH, so the mechanism remains a preclinical working model rather than a confirmed clinical pathway.
Typowe dawkowanie	No human dose - research compound only · Not applicable - no human use	200-500 mcg daily · 1-2x daily
Dawkowanie z badań	0.3 mg/mL (nearly 100% leukemia cell killing) · Research protocols only - no human use data · IV injection in animal studies - not for human use	200-500 mcg daily · 4-8 weeks typical · Subcutaneous injection or oral capsules
Typowy czas trwania	Research protocols only - no human use data	4-8 weeks typical
Podanie	-	Subcutaneous injection or oral capsules
Timing	Per research protocol With or without food (source-listed; no human-use basis supplied).	Morning, or as directed in the source context With or without food
Poziom dowodów	Przedkliniczne	Przedkliniczne
Mozliwe skutki uboczne	Limited safety information is available for this research compound. (Human safety data were not supplied.) The source reports in-vitro selectivity for cancer cells. (This is a laboratory observation, not a human safety finding.) No cytotoxicity was reported in normal fibroblasts and leukocytes. (Reported in vitro; it does not establish systemic safety.) +4 więcej Reported activity was temperature dependent, with 37°C described as optimal and 17°C as minimal. (Laboratory-condition observation.) No human clinical trials were reported. (Human adverse-effect frequency and severity are therefore unknown.) Systemic effects in humans are unknown. (No human clinical evidence was supplied.) Potential immunogenicity is unknown. (No human clinical evidence was supplied.)	Generally well tolerated (Reported by the source; human clinical safety evidence was not provided.) Injection-site reactions (Listed for injectable use.) Transient mild flu-like symptoms (Reported as mild and temporary in the source.) +4 więcej Mild gastrointestinal effects (Listed without additional severity detail.) Possible histamine release (Source advises caution for MCAS or histamine sensitivity; supporting human trial data was not provided.) Does not cause immunosuppression (Source reports this as a safety-related claim; corroborating clinical evidence was not supplied.) Cancer-history contraindication claim (Source lists this as a contraindication; independent clinical substantiation was not provided in the input.)
Podsumowanie researchu	The source characterizes a 2010 PNAS report by Sarafraz-Yazdi and colleagues as evidence for HDM-2 binding and cancer-cell lysis, and it mentions a separate 2010 intact-peptide lysis study. It also describes a 2022 Biomedicines publication as consistent with membrane-pore and selectivity findings in cell lines; according to the source, normal cells made to express membrane HDM-2 became susceptible. These accounts concern in-vitro, ex-vivo, and animal work. No completed human trial is reported to establish safety or anticancer benefit.	The supplied research summary places KPV in a preclinical evidence tier. It cites Dalmasso and colleagues in Gastroenterology in 2008 for PepT1-dependent uptake and reduced intestinal inflammation in experimental colitis models, including DSS and TNBS mouse models, alongside lower pro-inflammatory cytokine signals. A 2016 PMC-listed study is described as showing fewer tumors in a mouse model of colitis-associated cancer when KPV activity depended on PepT1. The source emphasizes that these are animal and in vitro findings and does not provide published randomized human trials for inflammatory bowel disease, eczema or other promoted uses.
Referencje	Źródło Źródło +3 więcej Źródło Źródło Źródło	Źródło Źródło +1 więcej Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

PNC27

KPV

Kategoria

Odporność

Znany tez jako

PNC-27, p53-HDM2 Disruptor Peptide, Anti-Cancer Peptide PNC-27

Lys-Pro-Val, Alpha-MSH fragment

Zatwierdzony przez FDA

Nie

Status kliniczny

Preclinical; reported in-vitro, ex-vivo human cancer-tissue, and animal research, with no human clinical trials reported.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical research ongoing; no human clinical-trial benefit evidence was provided

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Cancer research; tumor targeting; oncology research.

Gut inflammation, IBD, skin conditions and anti-inflammatory activity

Jak dziala

The source describes a p53-derived binding segment engaging HDM-2/MDM2 reported at the surface of some cancer cells. It proposes that the peptide's amphipathic helix-loop-helix conformation can enter the membrane and form pores, leading to necrotic lysis rather than apoptosis. It also reports mitochondrial membrane disruption after entry. Reported selectivity is attributed to normal cells lacking membrane-associated HDM-2, but this remains preclinical evidence.

KPV is described as a short alpha-MSH-derived peptide with a proposed anti-inflammatory mechanism. In the supplied evidence, KPV uptake is linked to PepT1 transport, particularly in inflamed intestinal tissue. After cellular entry, laboratory findings associate KPV with dampened NF-kB activity and reduced production of inflammatory mediators such as TNF-alpha, IL-1beta and IL-6. The source also states that KPV does not appear to act through the classic melanocortin receptors used by alpha-MSH, so the mechanism remains a preclinical working model rather than a confirmed clinical pathway.

Typowe dawkowanie

No human dose - research compound only · Not applicable - no human use

200-500 mcg daily · 1-2x daily

Dawkowanie z badań

0.3 mg/mL (nearly 100% leukemia cell killing) · Research protocols only - no human use data · IV injection in animal studies - not for human use

200-500 mcg daily · 4-8 weeks typical · Subcutaneous injection or oral capsules

Typowy czas trwania

Research protocols only - no human use data

4-8 weeks typical

Podanie

Subcutaneous injection or oral capsules

Timing

Per research protocol

With or without food (source-listed; no human-use basis supplied).

Morning, or as directed in the source context

With or without food

Poziom dowodów

Przedkliniczne

Mozliwe skutki uboczne

Limited safety information is available for this research compound. (Human safety data were not supplied.)
The source reports in-vitro selectivity for cancer cells. (This is a laboratory observation, not a human safety finding.)
No cytotoxicity was reported in normal fibroblasts and leukocytes. (Reported in vitro; it does not establish systemic safety.)

+4 więcej

Reported activity was temperature dependent, with 37°C described as optimal and 17°C as minimal. (Laboratory-condition observation.)
No human clinical trials were reported. (Human adverse-effect frequency and severity are therefore unknown.)
Systemic effects in humans are unknown. (No human clinical evidence was supplied.)
Potential immunogenicity is unknown. (No human clinical evidence was supplied.)

Generally well tolerated (Reported by the source; human clinical safety evidence was not provided.)
Injection-site reactions (Listed for injectable use.)
Transient mild flu-like symptoms (Reported as mild and temporary in the source.)

+4 więcej

Mild gastrointestinal effects (Listed without additional severity detail.)
Possible histamine release (Source advises caution for MCAS or histamine sensitivity; supporting human trial data was not provided.)
Does not cause immunosuppression (Source reports this as a safety-related claim; corroborating clinical evidence was not supplied.)
Cancer-history contraindication claim (Source lists this as a contraindication; independent clinical substantiation was not provided in the input.)

Podsumowanie researchu

The source characterizes a 2010 PNAS report by Sarafraz-Yazdi and colleagues as evidence for HDM-2 binding and cancer-cell lysis, and it mentions a separate 2010 intact-peptide lysis study. It also describes a 2022 Biomedicines publication as consistent with membrane-pore and selectivity findings in cell lines; according to the source, normal cells made to express membrane HDM-2 became susceptible. These accounts concern in-vitro, ex-vivo, and animal work. No completed human trial is reported to establish safety or anticancer benefit.

The supplied research summary places KPV in a preclinical evidence tier. It cites Dalmasso and colleagues in Gastroenterology in 2008 for PepT1-dependent uptake and reduced intestinal inflammation in experimental colitis models, including DSS and TNBS mouse models, alongside lower pro-inflammatory cytokine signals. A 2016 PMC-listed study is described as showing fewer tumors in a mouse model of colitis-associated cancer when KPV activity depended on PepT1. The source emphasizes that these are animal and in vitro findings and does not provide published randomized human trials for inflammatory bowel disease, eczema or other promoted uses.

Referencje

+3 więcej

+1 więcej

Pełny profil